3 active not recruiting. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 3 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Metaplasia: new trials by email Literature Review of Metaplasia trials Research Report on Metaplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration NG101 AAV gene therapy - Age-Related Macular Degeneration | Phase 1 / Phase 2 | Active not recruiting | Elisigen, Inc. | 20 | 2023-09-08 | 2026-09-10 |
| Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] ADVM-022 - Neovascular Age-related Macular Degeneration | Phase 2 | Active not recruiting | Adverum Biotechnologies, Inc. | 69 | 2022-08-23 | 2026-10-27 |
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD ABBV-RGX-314, Ranibizumab (LUCENTIS®) - AMD, nAMD | Phase 2 / Phase 3 | Active not recruiting | AbbVie | 671 | 2020-12-29 | 2026-04-28 |
Choroidal Neovascularization (3) · Eye Diseases (3) · Macular Degeneration (3) · Wet Macular Degeneration (3) · Retinal Degeneration (2) · Retinal Diseases (2) · Blindness (1)
Choroid Diseases (3) · Neovascularization, Pathologic (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Uveal Diseases (3) · Eye Diseases, Hereditary (2) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Retinal Degeneration (1) · Retinal Diseases (1) · Sensation Disorders (1) · Signs and Symptoms (1) · Vision Disorders (1)
Ranibizumab (1)
AbbVie (1) · Adverum Biotechnologies, Inc. (1) · Elisigen, Inc. (1)
United States (3) · Canada (1) · France (1) · United Kingdom (1)
Adam Turpcu, PhD (1) · Christopher D Riemann, MD (1)